Développement d'un inhibiteur pour une nouvelle cible thérapeutique (Hit to lead)

We seek to develop an inhibitor against a newly identified therapeutic target in our laboratory. Our focus will be on a chemical series derived from HTS screening, which has subsequently been optimized during a hit expansion phase. This request for proposal (RFP) concerns a hitto-lead optimization phase, which is expected to last for six months. The goal is to strengthen the structure-activity relationship (SAR) of our chemical series.